Pulmonary Research Institute at Hospital Groβhansdorf, Center for Pneumology and Thoracic Surgery, Groβhansdorf, Groβhansdorf 22927, Germany.
Thorax. 2012 Apr;67(4):302-8. doi: 10.1136/thoraxjnl-2011-201038. Epub 2012 Feb 28.
Interlobar fissure integrity has previously correlated with responsiveness to endobronchial lung volume reduction therapy in patients with advanced emphysema.
This report summarises the effect of interlobar fissure integrity on responses to treatment with a novel endoscopic tissue sealant (AeriSeal emphysematous lung sealant (ELS)) that collapses hyperinflated lung.
Fissure status, lung volumes, tissue density and disease heterogeneity were assessed radiographically in 28 patients (age 63.4±6.1 years, 20 men) with advanced upper lobe predominant emphysema (density=888.0±18.2 HU; upper lobe tissue density < -950 = 2.62±1.74). Post-treatment changes in lobar volume, pulmonary function, exercise capacity, symptoms and quality of life were compared in patients with complete fissures (CFs) and incomplete fissures (ICFs).
ELS therapy reduced lung volumes independent of interlobar fissure integrity. In patients with upper lobe emphysema and CFs, lobar volume reduction was 214±127 ml/treatment compared with 256±175 ml/treatment in those with ICFs (p=0.453). Reductions in gas trapping and improvements in spirometry, functional capacity and quality of life were similar in patients with CFs and ICFs. Stepwise multiple regression modelling confirmed that fissure integrity did not contribute to post-treatment changes in forced expiratory volume in 1 s, residual volume/total lung capacity ratio or lobar volume measured by CT analysis.
Interlobar fissure integrity, an important determinant of responsiveness to endobronchial lung volume reduction therapy in prior studies, had minimal impact on physiological and functional responses to ELS therapy in patients with severe upper lobe predominant emphysema.
Registration numbers for trials contributing to datasets in this report: NCT00884962, NCT01051258 and NCT01181466.
先前的研究表明,叶间裂的完整性与晚期肺气肿患者对支气管内肺减容治疗的反应性相关。
本报告总结了叶间裂完整性对新型内镜组织密封剂(AeriSeal 肺气肿肺密封剂(ELS))治疗反应的影响,该密封剂可使过度充气的肺塌陷。
在 28 例(年龄 63.4±6.1 岁,20 名男性)伴有严重上叶为主型肺气肿的患者(密度=888.0±18.2 HU;上叶组织密度<-950 = 2.62±1.74)中,通过影像学评估裂完整性、肺容积、组织密度和疾病异质性。比较完全叶间裂(CFs)和不完全叶间裂(ICFs)患者的治疗后肺叶容积、肺功能、运动能力、症状和生活质量变化。
ELS 治疗可独立于叶间裂完整性降低肺容积。在有上叶肺气肿和 CFs 的患者中,与 ICFs 患者(256±175 ml/治疗)相比,肺叶容积减少 214±127 ml/治疗(p=0.453)。CFs 和 ICFs 患者的气体陷闭减少、肺功能、运动能力和生活质量改善情况相似。逐步多元回归模型证实,裂完整性对 CT 分析测量的 1 秒用力呼气量、残气量/总肺容量比值或肺叶容积的治疗后变化无影响。
在先前的研究中,叶间裂完整性是支气管内肺减容治疗反应性的一个重要决定因素,但在严重上叶为主型肺气肿患者中,对 ELS 治疗的生理和功能反应影响较小。
本报告中数据集的试验注册编号:NCT00884962、NCT01051258 和 NCT01181466。